1. Clinical & Scientific Overview
Fluconazole (TIP-MED-000141, Reference Code [8.13]) is classified under
Antimicrobials — Systemic Antifungal Agents (Ch 08) as a Triazole Systemic Antifungal (Fungal Cytochrome P450 14-Alpha-Sterol Demethylase [CYP51] Inhibitor).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 08 [8.13], p. 99): Forcan (Cipla), Zocon (FDC Ltd), Fluka (Cipla), Syscan (Torrent), Onecan, AF-150 — Strengths & Dosage Forms: Oral Uncoated / Dispersible Tablets & Capsules: 50 mg, 150 mg, 200 mg, 400 mg; IV Infusion: 200 mg/100 mL; Ophthalmic Drops: 0.3% w/v
Oral Uncoated / Dispersible Tablets & Capsules: 50 mg, 150 mg, 200 mg, 400 mg; IV Infusion: 200 mg/100 mL; Ophthalmic Drops: 0.3% w/v
3. Mechanism of Action & Pharmacodynamics
Triazole Systemic Antifungal (Fungal Cytochrome P450 14-Alpha-Sterol Demethylase [CYP51] Inhibitor) acting on target receptor/enzyme pathways in Antimicrobials — Systemic Antifungal Agents (Ch 08): clinical efficacy is mediated via Triazole Systemic Antifungal (Fungal Cytochrome P450 14-Alpha-Sterol Demethylase [CYP51] Inhibitor) for Vulvovaginal candidiasis (single 150 mg oral dose); oropharyngeal and oesophageal candidiasis (e.g., steroid-inhaler thrush, immunocompromised); dermatophytosis (tinea corporis/cruris/pedis—150 mg once weekly for 4–6 weeks, though itraconazole/terbinafine are often preferred in recalcitrant Indian dermatophytosis) and tinea versicolor (400 mg single dose or 150–300 mg weekly); candiduria; cryptococcal meningitis..
4. Therapeutic Indications & Evidence-Supported Uses
- Vulvovaginal candidiasis (single 150 mg oral dose)
- oropharyngeal and oesophageal candidiasis (e
- , steroid-inhaler thrush, immunocompromised)
- dermatophytosis (tinea corporis/cruris/pedis—150 mg once weekly for 4–6 weeks, though itraconazole/terbinafine are often preferred in recalcitrant Indian dermatophytosis) and tinea versicolor (400 mg single dose or 150–300 mg weekly)
- candiduria
- cryptococcal meningitis
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: Highly Indication-Specific! • Vulvovaginal Candidiasis: 150 mg as a single one-time dose (in severe or SGLT2-inhibitor-associated candidiasis, a second 150 mg dose 72 hours later is often prescribed). • Tinea / Onychomycosis: 150 mg once weekly. • Oropharyngeal Candidiasis: 200 mg Day 1, then 100 mg once daily for 7–14 days. Follow physician prescription.
Administration & Meal Timing: With or without food (unlike itraconazole capsules [which require food and gastric acid] or voriconazole [which requires an empty stomach], fluconazole is >90% water-soluble and absorbed completely regardless of food or PPIs!). | Any consistent time of day.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Strictly renal-function dependent (excreted >80% unchanged in urine)! • For a single one-time 150 mg dose (vaginal candidiasis), no renal dose adjustment is required. • For multiple-dose regimens when CrCl ≤50 mL/min (not on dialysis): Give the standard loading dose on Day 1, then reduce all subsequent maintenance doses by 50%! (After haemodialysis: give 100% of recommended dose post-session). Hepatic: Monitor LFTs closely in multi-dose therapy; discontinue if jaundice or clinical hepatitis develops.
Renal: Strictly renal-function dependent (excreted >80% unchanged in urine)! • For a single one-time 150 mg dose (vaginal candidiasis), no renal dose adjustment is required. • For multiple-dose regimens when CrCl ≤50 mL/min (not on dialysis): Give the standard loading dose on Day 1, then reduce all subsequent maintenance doses by 50%! (After haemodialysis: give 100% of recommended dose post-session). Hepatic: Monitor LFTs closely in multi-dose therapy; discontinue if jaundice or clinical hepatitis develops.
Renal: Strictly renal-function dependent (excreted >80% unchanged in urine)! • For a single one-time 150 mg dose (vaginal candidiasis), no renal dose adjustment is required. • For multiple-dose regimens when CrCl ≤50 mL/min (not on dialysis): Give the standard loading dose on Day 1, then reduce all subsequent maintenance doses by 50%! (After haemodialysis: give 100% of recommended dose post-session). Hepatic: Monitor LFTs closely in multi-dose therapy; discontinue if jaundice or clinical hepatitis develops.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindicated with co-administration of cisapride, terfenadine, astemizole, pimozide, quinidine, or erythromycin (fatal torsades de pointes!). Caution in QTc prolongation, hepatic dysfunction, renal impairment, and pregnancy (Category D in high or multi-dose regimens; even single 150 mg oral dose in 1st trimester is linked to increased spontaneous abortion—use topical Clotrimazole vaginal pessaries instead in pregnancy!).
Key Clinical Precautions: Renal: Strictly renal-function dependent (excreted >80% unchanged in urine)! • For a single one-time 150 mg dose (vaginal candidiasis), no renal dose adjustment is required. • For multiple-dose regimens when CrCl ≤50 mL/min (not on dialysis): Give the standard loading dose on Day 1, then reduce all subsequent maintenance doses by 50%! (After haemodialysis: give 100% of recommended dose post-session). Hepatic: Monitor LFTs closely in multi-dose therapy; discontinue if jaundice or clinical hepatitis develops.
8. Adverse Effects Profile
- Nausea, abdominal pain, headache, mild diarrhoea, skin rash, transient hepatic transaminase elevation.
- QTc interval prolongation and torsades de pointes, severe hepatotoxicity/hepatic necrosis (rare, mostly in patients with underlying severe medical illness), Stevens-Johnson Syndrome (SJS) / TEN, adrenal insufficiency (at high doses), alopecia (reversible, with prolonged therapy).
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- POTENT INHIBITOR OF CYP2C9 AND CYP2C19, AND MODERATE INHIBITOR OF CYP3A4! (Note: Because fluconazole has a ~30-hour half-life, even a single 150 mg tablet inhibits CYP enzymes for 4 to 7 days after ingestion!): • Sulfonylureas (Glimepiride, Gliclazide, Glipizide): Blocks CYP2C9 breakdown -> causes severe, prolonged hypoglycaemia! • Warfarin / Acitrom: Blocks CYP2C9 -> doubles PT-INR and causes major bleeding! • Phenytoin: Blocks CYP2C9/2C19 -> causes acute phenytoin ataxia/nystagmus toxicity! • Clopidogrel: Blocks CYP2C19 activation of clopidogrel! • Statins (Atorvastatin, Simvastatin): Increases myopathy/rhabdomyolysis risk
- • QT-Prolonging Drugs: Additive arrhythmia risk with Domperidone, Ondansetron, Amiodarone, Levofloxacin, and Escitalopram
- • Losartan: Blocks CYP2C9 conversion of losartan to its active antihypertensive metabolite
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Verify the exact dosing schedule on the prescription (Single 1-tablet pack vs. Once-Weekly vs. Daily)—patients frequently mistake a 4-tablet weekly fungal strip for a 4-day daily course! Warn diabetic patients taking Dapagliflozin/Empagliflozin + Glimepiride (who frequently get genital fungal infections and are prescribed a 150 mg Fluconazole tablet) that Fluconazole can cause their Glimepiride to trigger low blood sugar over the next 3–5 days!
- Meal & Clock Timing Instruction: With or without food (unlike itraconazole capsules [which require food and gastric acid] or voriconazole [which requires an empty stomach], fluconazole is >90% water-soluble and absorbed completely regardless of food or PPIs!). (Any consistent time of day.)
- Missed Dose Protocol: If on once-weekly dosing and remembered within 1–2 days, take it; if on daily dosing, take as soon as remembered unless near next dose.
- Geriatric Dispensing Pearl: In elderly CGHS patients on Warfarin, Phenytoin, or Sulfonylureas, even a single 150 mg or weekly Fluconazole tablet can trigger dangerous toxicity—prefer topical antifungal creams (Clotrimazole/Luliconazole) for localised skin or genital candidiasis whenever possible!
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Uncoated / Dispersible Tablets & Capsules: 50 mg, 150 mg, 200 mg, 400 mg; IV Infusion: 200 mg/100 mL; Ophthalmic Drops: 0.3% w/v
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 08 [8.13] (p. 99)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [8.34] Terbinafine Hydrochloride & Griseofulvin — Allylamine Squalene Epoxidase Inhibitor & Microtubule Mitotic Inh
- [8.33]-C76 Voriconazole — Systemic Triazole Ergosterol (CYP51A1) Synthesis Inhibitor Antifu
- [8.34]-C77 Griseofulvin — Allylamine Squalene Epoxidase Inhibitor & Microtubule Mitotic Inh
- [8.33] Itraconazole & Voriconazole — Systemic Triazole Ergosterol (CYP51A1) Synthesis Inhibitor Antifu